Sophiris Bio Inc.

Sophiris Bio Inc. will forge ahead with plans for a Phase III study of its prostate cancer candidate topsalysin despite final data from a Phase IIb study showing that a second administration of the d

Sophiris Bio Inc. CEO Randy Woods said a cloud has lifted over its intratumoral injection agent topsalysin now that an investigation concluded that a patient fatality in a small Phase IIb study of lo

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

Investors responded negatively to Sophiris Bio Inc. ’s data release for its Phase IIb localized prostate cancer therapy topsalysin on June 25, as the report of one patient death among 11 who received